Youssef Arshoun, MD
Radiation Oncology · Natrona Heights, PANPI 1780683805
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.7% of the total across 17 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 9 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $216 and has fallen 87.7% since, to $27 in 2024. That places this record below the midpoint for radiation oncology clinicians in PA, where the typical reported total is $405.
Across 17 payments — averaging $19.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$64
- E.r. Squibb & Sons, L.L.C.$64
- Merck$58
- Boston Scientific$42
- Incyte Corporation$33
- Daiichi Sankyo Inc.$27
- plus $44 from 3 others
Across 6 payments — averaging $1823.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Tactile Systems Technology Inc$11K
What the payments were for
- Food & beverage$31896%
- Education$144%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 4 | $64 |
| E.r. Squibb & Sons, L.L.C. | 3 | $64 |
| Merck | 3 | $58 |
| Boston Scientific | 1 | $42 |
| Incyte Corporation | 2 | $33 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Clovis Oncology, Inc. | 1 | $15 |
| AstraZeneca | 1 | $15 |
| AMAG Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$332 in reported general payments places this provider in the 45th percentile of 339 radiation oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 54 | $910 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Natrona Heights
- Chirag ShahPittsburgh$344K
- Neil TaunkPhiladelphia$203K
- Wenyin ShiPhiladelphia$119K
- Navesh SharmaYork$106K
- Zachary HornePittsburgh$56K
- Yvonne MoweryPittsburgh$55K
- Kevin NeadPhiladelphia$50K
- Adam DickerPhiladelphia$46K
- Ajay BhatnagarHershey$42K
- Tinatin ChabrashviliPhiladelphia$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.